Passage looks to offload lead program, 2 other assets fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
PHILADELPHIA, Nov. 17, 2023 Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced.
Passage Bio, Inc. (NASDAQ:PASG – Free Report) – Equities research analysts at Wedbush cut their FY2023 EPS estimates for Passage Bio in a note issued to investors on Monday, November 13th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($1.96) for the year, down from their previous estimate […]
Passage Bio (NASDAQ:PASG – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03), MarketWatch Earnings reports. Passage Bio Price Performance NASDAQ PASG opened at $0.66 on Wednesday. The business has a fifty day moving average […]
Passage Bio (NASDAQ:PASG) Posts Quarterly Earnings Results, Misses Estimates By $0 03 EPS kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.